(Q39733019)

14 September 2017

title

SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer (English)

1 reference

14 September 2017

main subject

phase II clinical trial

0 references

1 reference

R P Symonds

1

1 reference

14 September 2017

S E Davidson

2

1 reference

14 September 2017

S Chan

3

1 reference

14 September 2017

N S Reed

4

1 reference

14 September 2017

T McMahon

5

1 reference

14 September 2017

D Rai

6

1 reference

14 September 2017

S Harden

7

1 reference

14 September 2017

J Paul

8

1 reference

14 September 2017

Scottish Gynaecological Cancer Trials Group, Beatson West of Scotland Cancer Centre

9

1 reference

14 September 2017

language of work or name

English

0 references

publication date

2 July 2011

1 reference

14 September 2017

1 reference

14 September 2017

volume

123

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

105-109

1 reference

Global patterns of cancer incidence and mortality rates and trends

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

Estimation of Relative Risk from Individually Matched Series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.001

10.1016/J.YGYNO.2011.06.001

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference